GlassScriptPhysician profile
Lauren M Ruskell
NPI 1932576584
$2,981.49
in general payments reported to CMS, 2019-2025
37 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $834 · 2022: $669 · 2023: $733 · 2024: $339 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387 · Education: $91.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.63 |
| Education | $91.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $558.09 | 2021-2023 | Jemperli, Zejula, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $366.11 | 2021-2025 | Tagrisso, Imfinzi, Calquence |
| Pharmacyclics LLC, An Abbvie Company | $198.45 | 2021-2023 | Epkinly, Imbruvica |
| Daiichi Sankyo INC. | $190.60 | 2021-2024 | Enhertu, Injectafer |
| Lilly USA, LLC | $161.11 | 2023-2025 | Jaypirca, Verzenio |
| Abbvie INC. | $153.61 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $141.64 | 2022-2025 | |
| Immunogen, INC. | $124.99 | 2023 | Elahere |
| Myriad Genetic Laboratories, INC. | $116.67 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.62 | 2021-2024 | Alunbrig |
| Janssen Biotech, INC. | $86.29 | 2021-2022 | |
| Smith+Nephew, INC. | $77.16 | 2025 | Collagenase Santyl |
| Exelixis INC. | $76.34 | 2023-2024 | Cabometyx |
| Amgen INC. | $71.15 | 2021-2022 | |
| Beigene USA, INC. | $48.73 | 2021-2024 | Brukinsa |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37.49 | 2021-2022 | |
| Sobi, INC | $37.27 | 2022-2025 | |
| Dova Pharmaceuticals | $35.49 | 2021 | |
| Puma Biotechnology, INC. | $33.28 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $32.98 | 2021-2022 | |
| Emd Serono, INC. | $29.10 | 2021 | |
| Taiho Oncology, INC. | $28.62 | 2021-2022 | |
| Springworks Therapeutics, INC. | $26.45 | 2024 | Ogsiveo |
| Ipsen Biopharmaceuticals, INC | $26.07 | 2025 | Onivyde |
| Coherus Oncology, INC. | $25.38 | 2021 | |
| Deciphera Pharmaceuticals INC. | $22.89 | 2025 | Qinlock, Romvimza |
| Servier Pharmaceuticals LLC | $22.02 | 2022 | |
| Incyte Corporation | $21.86 | 2023 | Monjuvi, Jakafi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $20.78 | 2023 | Libtayo |
| Kite Pharma, INC. | $19.73 | 2023 | |
| Genmab U.S., INC. | $18.51 | 2023 | Epkinly |
| Acrotech Biopharma INC. | $15.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.59 | 2024 | |
| Pharmacosmos Therapeutics INC. | $15.33 | 2023 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.11 | 2025 | |
| Celgene Corporation | $11.68 | 2021 | |
| Genentech USA, INC. | $8.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Ruskell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.